Evidence map›Paper›PMID 36200241›Full record

SynthesisAnti-cancer agents in medicinal chemistry2024

A Number of the N-terminal RASSF Family: RASSF7.

Yang Xu, Wei Du, Yongshuang Xiao, Keyu Gao, Jie Li, Shuofeng Li

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Anti-cancer agents in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yang XuDepartment of Urology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, People's Republic of China.
Wei DuDepartment of Urology, Wanbei Coal-Electricity Group General Hospital, Suzhou 234000, People's Republic of China.
Yongshuang XiaoDepartment of Urology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, People's Republic of China.
Keyu GaoDepartment of Urology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, People's Republic of China.
Jie LiDepartment of Urology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, People's Republic of China.
Shuofeng LiDepartment of Urology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, People's Republic of China.
Xuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Ras association domain family 7 (RASSF7, also named HRC1), a potential tumor-related gene, located on human chromosome 11p15, has been identified as an important member of the N-terminal RASSF family. Whereas, the molecular biological mechanisms of RASSF7 in tumorigenesis remain to be further established. We perform a systematic review of the literature and assessment from PUBMED and MEDLINE databases in this article. RASSF7 plays a significant role in mitosis, microtubule growth, apoptosis, proliferation and differentiation. Many research literature shows that the RASSF7 could promote the occurrence and advance of human tumors by regulating Aurora B, MKK4, MKK7, JNK, YAP, MEK, and ERK, whereas, it might inhibit c-Myc and thus lead to the suppression of tumorigenesis. The pregulation of RASSF7 often occurs in various malignancies such as lung cancer, neuroblastoma, thyroid neoplasm, hepatocellular cancer, breast cancer and gastric cancer. The expression stage of RASSF7 is positively correlated with the tumor TNM stage. In this review, we primarily elaborate on the acknowledged structure and progress in the various biomechanisms and research advances of RASSF7, especially the potential relevant signaling pathways. We hope that RASSF7 , a prospective therapeutic target for human malignancies, could play an available role in future anti-cancer treatment.

Indexed as

NeoplasmsAntineoplastic AgentsHumansTranscription FactorsTumor Suppressor ProteinsAntineoplastic AgentsRASSF7 protein, humanTranscription FactorsTumor Suppressor ProteinsCpG islandsmalignancyN-terminal.RASSF7therapeutic targettumor promoter

Identifiers

PMID36200241
OpenAlexW4298138347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.